Toy, Mehlika; Onder, Fatih; Idilman, Ramazan; Kabacam, … - In: The European Journal of Health Economics 13 (2012) 5, pp. 663-676
In a country with considerable amount of active CHB patients, monotherapy with a highly potent third generation drug has the most health-gain, and is cost-effective in both HBeAg-positive and negative in all stages of liver disease. </AbstractSection> Copyright The Author(s) 2012
